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The University of Michigan 
The potential of tracking tasks for use in clin- 
ical applications has been recognized for many 
years. While investigators have demonstrated 
the usefulness of these tasks in drug research and 
in measuring the performance of pathological 
subjects, (e.g., Stark and Iida (ref. 1) and Angel 
et al. (ref. 2) few have made effective use of track- 
ing measures in clinical trials. At the University 
of Michigan’s Neurology Research Laboratory, 
a tracking test battery has been applied in a drug 
trial designed to compare the efficacy of L-DOPA 
and amantadine to that of L-DOPA and placebo 
in the treatment of 28 patients with Parkinson’s 
disease. The drug trial provided an ideal oppor- 
tunity for objectively evaluating the usefulness of 
tracking tests in assessing changes in neurologic 
function. 
Evaluating changes in patient performance 
resulting from disease progression and controlled 
clinical trials is of great importance in establish- 
ing effective treatment programs. Clinicians are 
usually able to classify a given neurologic func- 
tion of the patient into broad categories such as 
supernormal, normal, and abnormal (mild, mod- 
erate, or severe) ; but they often have difficulty 
in detecting small but significant changes in the 
patient’s function over time. One attempt at  a 
more objective and quantitative neurologic ex- 
amination was initiated a t  The University of 
Michigan Medical Center several years ago by 
Dr. Wallace W. Tourtellotte. Investigators have 
long known that the total performance capabili- 
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ties of an individual cannot be specified on the 
basis of a single performance test. For this reason, 
Dr. Tourtellotte devised a battery of sensory 
and motor performance tests which are now col- 
lectively referred to as the Clinical Quantitative 
Neurological Examination (CQNE) (table 1). 
TABLE 1 .-The Clinical Quantitative Neurological 
Examination (CQNE) Test Items 
Vision: Visual acuity 
Upper Extremities- 
Strength of movements: 
Grip 
Wrist dorsillexion 
Shoulder abduction 
Control of movements: 
Steadiness 
Hole steadiness, supported and unsupported 
Force steadiness, supported and unsupported 
Finger tremor, resting and sustension 
Simple reaction time 
Speed of hand 
Speed-coordination of hand 
Rotary pursuit 
Finger dexterity 
Purdue Pegboard 
Pencil rotation 
Fatigue of movements: 
Grip strength 
Speed of hand 
Speed-coordination of hand 
Touch, hand 
Vibration sense, index b g e r  
Position Bense 
Two-point discrimination 
Sensation: 
Considerable experience has been gained with 
the CQNE as it has been used in a number of 
studies using asymptomatic subjects to obtain 
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normative data and in several therapeutic trials 
involving multiple sclerosis and Parkinson’s dis- 
ease patients (Tourtellotte et al. (ref. 3) and 
Kuzma et al. (ref. 4)). 
As part of a continuing effort to improve the 
clinical testing program, a tracking test battery 
was studied as a possible source of future tests for 
inclusion in the CQNE. To be effective in a 
clinical environment, the battery had to pro- 
vide measurements that required minimum run 
lengths and the fewest trials possible to establish 
stable parameter estimates. Extensive training 
time was a luxury that simply could not be 
afforded. Furthermore, all tests and measures 
had to allow the use of on-line data reduction 
schemes. The battery that was selected is very 
similar to the one described by Jex and Allen 
at last year’s meeting (ref. 5) ;  it includes step 
tracking, random tracking, and critical tracking 
(table 2). The tests were kept as simple, yet as 
comprehensive and challenging, as possible. 
Modifications in the display screen and control 
stick were necessary to accommodate patients 
with various sensori-motor disabilities. 
Whenever new quantitative tests for measur- 
ing neurologic disorders are developed it is of 
interest to examine the performance of normal 
subjects as well as patients on the tests. Relia- 
bilities and learning effects are more effectively 
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measured with normal subjects due to the possi- 
bility of large variations in patients’ perfor- 
mance which can be justifiablyattributed to their 
pathological condition. Ten age-matched nor- 
mals were used in a test-retest study to determine 
reliability measures for the tracking battery 
(table 3). All reliability coefficients were found 
to be significant at  or above the 5 percent level 
with the exception of movement time for a right 
to left transition, and the coefficient for this test 
TABLE 3.-Reliability of Tracking Test Batterg 
Involving 10 Matched Normals With a 3 Week 
Interval Between the First and Second 
Examinations 
2r - 
Test r1 1 +I4 
- ~ ~ 
Step tracking 
Reaction time, right to left 3 0.75 0.86 
Reaction time, left to right 4 .82 .90 
Movement time, right to left .60 .75 
Movement time, left to right a .67 .a0 
Integral of absolute error 6 .91 .95 
Reciprocal of critical root 6 .96 .98 
Random tracking 
Critical tracking 
1 Pearson product moment correlation coefficient. 
2 Spearman-Brown split-half correlation formula. 
3 ~ 1 . 0 5 .  ‘ ~ 5 . 0 1 .  6~5.001.  
TABLE 2 .4enera l  Tracking Task Descriptions 
FORCING 
Type of Controlled Performance 
tracking Forcing function Display element measures 
Step Rectangular pulse Pursuit K Reaction time, 
with alternating movement time * 14 centimeter 
amplitude and pulse 
width from 2.7 to 
5.7 sec. 
Random Random noise with Compensatory K Integral of abso- 
cutoff frequency of 
1.0 rad/sec. 
lute error 
Critical None 
Reciprocal of cri- Compensatory -. K Xo = 1.0 rad/sec s--x’ tical root 
h =0.05 rad/sec 
J 
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TABLE $.--Learning in Tracking Test Battery Involving 10 Matched Normals 
With a 3 Week Interval Between the First and Second Examinations 
Test 
Exam I 
Mean SD 
Exam II 
Mean SD Difference % Change 1 t-DSerence t-% Change 
Step tracking 2 
Reaction time, right 
Reaction time, left 
Movement time, 
Movement time, 
Random Tracking 3 
to left 308 44 305 43 -3 - . 3  .27 .10 
to right 297 37 297 51 0 - . 2  . 00 .07 
right to left 510 80 493 106 - 17 - 2.7 .62 .53 
left to right 596 109 530 116 - 66 -10.5 2.29 2.41 4 
Integral of absolute 
error 1.93 .54 1.89 .52 -.04 - 1.4 .68 .35 
Critical tracking 2 
Reciprocal of critical 
root 371 56 361 61 - 10 - 2.6 1.77 1.79 
10 
Score 2i-Score li 
1 % Change =- x 100. 10 Score l i  
i-i 
2 Units are in milliseconds. 
centimeter-seconds 
aecond a Units are in 
4=p5.05. 
measure just barely missed the cutoff point. The 
same group of 10 normals was used to measure 
learning effects (table 4). Although all test scores 
showed an improvement on the aecond exam, 
none of the improvements were statistically 
significant. 
Another important reason for using normal 
subjects on new tests is to establish normative 
performance levels. Since it is the goal of the 
physician to bring the performance of patients to 
the predisease level, it is meaningful to express 
patient data as a percentage of that obtained 
from matched normal controls. This was done 
for the drug study, which used a randomized, 
double-blinded, crossover design. The 28 Park- 
inson’s disease patients were randomly assigned 
to two groups, the first group receiving L-DOPA 
+amantadine first and L-DOPA+placebo sec- 
ond, with the second group receiving just the 
opposite schedule (table 5 ) .  Treatment groups 
were combined for analysis, and scores were 
expressed as a percentage of matched normal 
levels (table 6). Relative to the normal subjects, 
patients performed better on step tracking and 
critical tracking than on random tracking. Im- 
provements were modest when amantadine was 
taken in addition to L-DOPA. 
TABLE 5.-Experimental Paradigm 
Medication taken during week 
No. of 
Group patients 1-3 4-6 
1 14 L - D + A  * L- D + P  
2 14 L-D+P L- D + A  
* L- D  =L-DOPA. A =Amantadine. 
P =Placebo. 
Based on other tests administered in the drug 
trial, the effect of adding amantadine to L-DOPA 
was found t o  be beneficial but weak. Thus, 
while the trends in the CQNE scores favored 
L-DOPA+ amantadine, only grip strength, hand 
coordination, pencil rotation, 2-point discrimina- 
tion, and resting tremor showed statistically 
Significant changes. The tracking test mea- 
sures all showed improvements favoring the 
L-DOPA+amantadine treatment group (table 
7). The critical task measure and left to right 
movement time showed improvements significant 
a t  the 5 percent level. While changes in random 
tracking scores and right to left reaction time 
scores were 10 percent or more, large variations 
in scores among patients prevented these changes 
from being statistically significant. The tracking 
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TABLE 6.-Performance of Patients in the Tracking Test Battery Expressed 
as a Percentage of Matched Adult Normal Function 
Test 
Step tracking 1 
Reaction time, right to left 
Reaction time, left to right 
Movement time, right to left 
Movement time, left to right 
Integral of absolute error 
Reciprocal of critical root 
Random tracking 
Critical tracking * 
Matched adult 
normal function 
Mean k2SD 
Patients on 
placebo 
% SD 
303 f 78 
294 k 67 
489 5 220 
568 f 234 
1 .895 1.16 
362 f 128 
83 19 
83 17 
78 22 
76 22 
61 23 
78 17 
Patients on 
drugs 
% SD 
90 22 
86 18 
80 20 
84 23 
65 17 
81 18 
1 Units are in millisec. 
centimeter-sec 
sec Units are in 
TABLE 7.-Results of Tracking Test Battery Involving 28 Parkinson Patients: 
Comparison Between L-DOPA +Placebo and L-DOPA i- Amantadine Treatment Groups 
L-DOPA + L-DOPA + 
amantadine placebo 
Test Mean SD Mean SD Difference % Change 1 &Difference t% Change 
Step tracking 
Reaction time, 
right to left 
Reaction time, 
left to right 
Movement time, 
right to left 
Movement time, 
left to right 
Random tracking 
Integral of 
Critical tracking 
Reciprocal of 
critical root 
absolute error 
359 
358 
642 
717 
3.04 
463 
91 385 
84 368 
145 679 
191 820 
* 74 3.36 
96 486 
102 27 10 1.61 2.32 4 
81 10 4 .75 1.32 
215 4 7 1.18 1.46 
289 10 16 2.32 2.89 5 
1.35 .32 11 1.42 1.66 
110 22 5 2.23 2.58 
centimeter-sec 
see a Units are in % Change=- 1 2 Score 2, -Score 1%. 
28 Score li 4pS.05. 6pS.01. 
i = l  
a Units are in millisec. 
measures still appeared to be at least as sensitive tion, test data, subject requirements, and 
as most measures in the CQNE in detecting examiner-requirements (table 8). The direct 
changes in performance. application of tracking tasks to a clinical trial has 
The final selection of a test for inclusion in the shown that they are indeed capable of satisfying 
CQNE depends upon the test’s satisfactory ful- these criteria. In closing, it should be mentioned 
fillment of a number of criteria relating to the that tracking tasks and other quantitative testing 
neurological function being tested, instrumenta- procedures are not meant as a substitute for 
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TABLE 8.--Criteria for Test Seledion 
Criteria related to the neurological fungtion tested: 
Criteria related to the instrument: 
The function must relate meaningfully to the status of the subject’s nervous system. 
The instrument must be small and capable of being used in a small area. 
Initial, operating, and maintenance costs of the instrument must; not be prohibitive. 
The data must be truly quantitative, i.e., a t  least of interval strength. 
The data must be objective, Le., reliable. 
The data must be sensitive enough to detect changes in the neurological function being 
Criteria related to the test data: 
evaluated. 
Criteria related to the subject: 
same time the test should not be beyond the ability of the patient. 
The “supernormal” healthy young adult should be challenged by the test, and yet a t  the 
The subject should be reasonably interested and motivated by the test. 
Learning effects should be at a minimum. 
The subject must not be so fatigued by the test as to prohibit the completion of succeeding 
The idea of the test must be simple enough to be easily communicated to the subject. 
A trained physical therapist must be capable of administering the test. 
tests in the battery. 
Criteria related to the examiner: 
sound clinical judgement, but they do provide the 
medical investigator with information that is 
often impossible to obtain from observation 
alone, particularly in detecting and documenting 
changes in a patient’s condition. 
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